Evidence mapPaperPMID 29326107Full record

ArticleDiabetes care2018

Shylaja Srinivasan, Varinderpal Kaur, Bindu Chamarthi, Katherine R Littleton, Ling Chen, Alisa K Manning, Jordi Merino, Melissa K Thomas, Margo Hudson, Allison Goldfine and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Diabetes care, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. The direct targets of metformin in diabetes and beyond.Trends in endocrinology and metabolism: TEM · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Association of GLP1R Polymorphisms With the Incretin Response.The Journal of clinical endocrinology and metabolism · 2022
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Shylaja SrinivasanPediatric Endocrine Unit, Massachusetts General Hospital, Boston, MA.
Varinderpal KaurDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Bindu ChamarthiDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA.
Katherine R LittletonDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Ling ChenDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Alisa K ManningDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Jordi MerinoDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Melissa K ThomasEli Lilly and Company, Indianapolis, IN.
Margo HudsonDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA.
Allison GoldfineDepartment of Medicine, Harvard Medical School, Boston, MA.
Jose C FlorezDiabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA jcflorez@mgh.harvard.edu.ORCID 0000-0002-1730-9325
Massachusetts General Hospital · USBrigham and Women's Hospital · USBroad Institute · USEli Lilly (United States) · USHarvard University · USJoslin Diabetes Center · US

Funding

ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · MASSACHUSETTS GENERAL HOSPITAL · 1985 to 2005
$26.1M
PILOT STUDY--SECRETORY TARGETING IN PANCREATIC B CELLSP30DK036836 · JOSLIN DIABETES CENTER · 1986 to 2025
$12.1M
Training Program in Pediatric EndocrinologyT32DK007161 · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 1986 to 2025
$1.7M
NCATS NIH HHS UL1 TR000170NCRR NIH HHS M01 RR001066NCRR NIH HHS UL1 RR025758NIDDK NIH HHS K24 DK110550NIDDK NIH HHS P30 DK036836NIDDK NIH HHS R01 DK088214NIDDK NIH HHS R03 DK077675NIDDK NIH HHS T32 DK007161
6 · The paper itself

Abstract

objectiveThe rs7903146 T allele in transcription factor 7 like 2 ( RESEARCH DESIGN AND

methodsWe genotyped rs7903146 in 608 individuals without diabetes and recorded biochemical data before and after

resultsTT risk-allele homozygotes had 1.6 mg/dL higher baseline fasting glucose levels and 2.5 pg/mL lower glucagon levels per T allele than carriers of other genotypes at baseline. In a subset of participants, the T allele was associated with higher basal glucagon-like peptide 1 (GLP-1) levels at visit 1 (β = 1.52,

conclusionsOur findings demonstrate that common variation at

Indexed as

Polymorphism, Single NucleotideAdultAgedAllelesBlood GlucoseDiabetes Mellitus, Type 2FemaleGenotyping TechniquesGlipizideGlucagonGlucagon-Like Peptide 1Glucose Tolerance TestHumansIncretinsMaleMetforminBlood GlucoseGlipizideGlucagonGlucagon-Like Peptide 1IncretinsMetforminSulfonylurea CompoundsTCF7L2 protein, humanTranscription Factor 7-Like 2 Protein

Identifiers

PMID29326107
PMCPMC5829963
OpenAlexW2783375883

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.